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Abstract 
Introduction: Immunoglobulin A vasculitis (IgAV) is the most common form of vasculitis in children. Nephritis in the course of this disease 
(IgAVN) is observed in 30–50% of patients and might lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Finding 
a non-invasive biomarker to distinguish initially between patients with and without nephritis and to facilitate a therapeutic decision to 
reduce the risk of long-term renal impairment is currently the target of much research. The aim of this study was to evaluate the adipo-
nectin concentration in children with IgAV and estimate whether it might be used as a marker of IgAVN.
Material and methods: The study involved 29 IgAV children and 34 healthy controls. Eleven (38%) patients had renal involvement 
(IgAV-N) and 18 (62%) did not exhibit nephritis (IgAV-noN). The serum adiponectin level was estimated in children in an acute phase 
of IgAV and after 2–6 months during a follow-up visit. The relationship between the concentration of adiponectin and anthropometric 
measurements, epidemiological data and laboratory parameters were evaluated. 
Results: The concentration of adiponectin in serum was significantly higher in children with acute phase of IgAV as compared to the 
control group (p < 0.001), and in patients without renal involvement in comparison with IgAV-N children (p < 0.049). In analysis of cor-
relation we found a negative relationship between adiponectin level and serum creatinine concentration (r = –0.437, p = 0.02). The logistic 
regression evaluation demonstrated that a low adiponectin level increased the risk of nephritis in the course of IgAV.  
Conclusions: Our study revealed that the serum adiponectin level increased markedly in patients with IgAV. We also documented that higher 
risk of nephritis in the course of the disease was associated with lower concentration of this hormone. (Endokrynol Pol 2020; 71 (6): 512–517)
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Introduction
Immunoglobulin A vasculitis (IgAV), previously re-
ported as Henoch-Schönlein Purpura (HSP), is the most 
common form of vasculitis in children, with an annual 
incidence estimated at 3–26.7/100,000/year [1]. The most 
typical symptom of IgAV is skin involvement, mainly 
presenting as a palpable purpura, which is often associ-
ated with systemic manifestations, including gastroin-
testinal pain and bleeding, arthralgia and/or arthritis, 
and glomerulonephritis. Although most symptoms 
are mild and self-limiting, renal involvement, which 
is observed in 30–50% of children in the course of the 
disease, is the most likely to result in long-term morbid-
ity and mortality [2].
It is unknown why only some patients with IgAV 
experience renal injury. In recent years the target of 
much research was to find novel non-invasive bio-
markers for the prediction of nephritis in the course 
of this disease. 
Taking into account that the main cause of IgAV 
is small vessels inflammation we decided to evaluate 
adiponectin concentration in children suffering from 
this disease. Encouraged by the latest promising reports 
suggesting the role of this hormone in preventing in-
flammation and sclerosis in IgAN patients [3–5], we also 
tried to estimate whether its concentration is associated 
with renal involvement and if it is able to initially distin-
guish patients with higher risk of developing nephritis.
Material and methods
The study group comprised 29 children with IgAV. Diagnosis of 
the disease was based on the EULAR/PRINTO/PRES criteria [6]. 
Renal involvement was defined as the presence of haematuria: > 
5 erythrocytes/high-power field and/or proteinuria: > 30 mg/mmol 
of urine protein/creatinine ratio (UP/UC ratio) and/or estimated 
glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. 
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nephrological complications in the course of the disease. p<0.05 
was considered significant.
Results
The children from the study and control group did 
not differ significantly in terms of anthropometric and 
blood pressure measurements (Tab. 1). 
Characteristics of IgAV patients at inclusion
In our study group 11 (37.9%) patients had renal in-
volvement (IgAV-N) and 18 (62.1%) did not exhibit 
nephritis (IgAV-noN). In patients with diagnosed IgAV 
we observed male predominance (58.6% vs. 41.4%); 
however, it was more pronounced in children from 
the IgAV-N group (90.9% vs. 9.1%, p = 0.006) (Tab. 1). 
The IgAV-N patients had significantly higher concen-
trations of creatinine (p = 0.048) and lower values of 
eGFR (p = 0.004) than children from the IgAV-noN 
group (Tab. 2).
Comparison of adiponectin concentrations 
in IgAV and control group patients
The concentration of adiponectin in serum was signifi-
cantly higher in children with acute phase of IgAV as 
compared to the control group (p < 0.001) (Fig. 1). More-
Thirty-four children hospitalised for nocturnal enuresis or present-
ing with procedures of one-day surgery were included into the 
control group matched in terms of age and gender to the study 
group. All children enrolled into the study were in stable clinical 
condition, proven by medical history, physical examination, and 
performed basic laboratory tests results. The patients with im-
munological diseases, symptoms of current infection, or incorrect 
laboratory test results were excluded from the controls.  
The study was approved by the Bioethics Committee of the Medi-
cal University of Silesia in Katowice (Resolution No. KNW/022/
KB1/128/16), and written consent was obtained from parents or 
legal guardians, and/or patients.
Laboratory assays
Blood samples for laboratory tests from patients belonging to the 
study group were collected during the first few days after the 
patient’s admission to the hospital in an acute phase of IgAV and 
after 2–6 months during a follow-up visit in a kidney outpatient 
clinic. Determination of adiponectin concentration was performed 
using ELISA kits (TECOmedical AG, Switzerland) according to the 
manufacturer’s protocol.
Statistical analysis
All statistical analyses were performed using licensed version 10.0 
software Statistica (StartSoft Inc., USA). For all parameters, the 
normality of distribution was determined by the Shapiro-Wilk test. 
For comparisons of variables with normal distribution Student’s 
t-test was used. The non-parametric Mann-Whitney U-test was 
used for comparisons of parameters with distribution diverged from 
the normal one. Correlations were analysed with Spearman test. 
To analyse associations between quantitative variables Pearson’s 
chi-squared test was performed. Logistic regression analysis was 
used to assess the usefulness of evaluating adiponectin in detecting 
Table 1. Demographic characteristics of children with immunoglobulin A vasculitis at inclusion and children from the control 
group
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110.6 ± 13.3 113.4 ± 13.2 108.5 ± 13.4 114.3 ± 12.1
DBP [mm Hg]
[mean ± SD]
68.7 ± 9.2 69.2 ± 5.4 68.3 ± 11.6 71.1 ± 10.3
MAP [mm Hg]
[mean ± SD]
82.7 ± 9.1 83.9 ± 6.3 81.7 ± 11.0 85.5 ± 9.0
IgAV-N — patients with IgAV and nephritis; IgAV-noN — patients with IgAV and without nephritis; IQR — interquartile range; SD — standard deviation;  
BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; MAP — mean arterial pressure; *p < 0.05 boys from IgAV-N group  
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Skin involvement, n (%)
Joint involvement, n (%)
Gastrointestinal involvement, n (%)
Renal involvement, n (%)
Haematuria, n (%)
Proteinuria, n (%)
Haematuria and proteinuria, n (%)
Hypertension, n (%)





























HGB [g/dL] [mean ±  SD]
WBC [×103/µL] [mean ±  SD]
PLT [×103/µL] [mean ±  SD]
IgA [g/L] [median (IQR)]
Serum creatinine [µmol/L]
[median (IQR)]
eGFR [mL/min/1.73 m2] 
[median (IQR)]
Serum urea [mmol/l] [mean ± SD]































eGFR — estimated glomerular filtration rate; HGB — haemoglobin level; WBC — white blood count; PLT — platelet count; *p < 0.005 IgAV-N vs. IgAV-noN; 
**p < 0.05 IgAV-N vs. IgAV-noN
Figure 1. Comparison between the concentration of serum adiponectin in children with immunoglobulin A vasculitis and patients 
from the control group. *p < 0.005 serum adiponectin level in IgAV group at inclusion vs. control group. #p < 0.005 serum 




































Figure 2. Comparison between concentrations of serum adiponectin. A. In girls and boys from the control group (p > 0.5 serum 
adiponectin level in boys vs. girls from the control group); B. In girls and boys with IgAV (*p < 0.005 serum adiponectin level 
at inclusion in girls vs. boys with IgAV, #p < 0.05 serum adiponectin level at follow-up in girls vs. boys with IgAV); C. In children 
from IgAV-N and IgAV-noN groups (*p < 0.05 serum adiponectin level in IgAV-noN vs. IgAV-N group at inclusion, #p < 0.005 
serum adiponectin level in IgAV-noN at inclusion vs. values at follow-up,**p < 0.005 serum adiponectin level in IgAV-noN 
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over, it was significantly higher in IgAV girls (p = 0.047) 
and in the IgAV-noN group (p = 0.049) (Fig. 2). 
Logistic regression analysis for possible risk 
factors of renal involvement in the course of IgAV
Logistic regression analysis in the univariate model 
of adiponectin and renal involvement in the course 
of IgAV showed that a higher risk of nephritis was 
associated with lower concentration of this hormone 
(p = 0.042).
Characteristics of IgAV patients at follow-up
After six months one child (3.4%) was lost to follow-up. 
No child developed de novo renal involvement or 
renal failure. The renal prognosis in most patients was 
good; only one (9.1%) still presented nephrotic range 
proteinuria. Eight (72.7%) children had haematuria, 
four (36.4%) had albuminuria, and one (9.1%) had 
haematuria and proteinuria. All children had normal 
eGFR.
Concentration of adiponectin in IgAV patients 
at follow-up and comparison of these results 
with values obtained at inclusion
In all IgAV patients the concentration of adiponectin 
was significantly lower at follow-up compared to the 
levels obtained at inclusion (p < 0.001). In addition, the 
values were still significantly higher in comparison to 
the control group (p < 0.05) (Fig. 1). Only in children 
from the IgAV-N group was the concentration of 
adiponectin in serum not changed significantly after 
several months, and it remained markedly lower than 
in children without nephritis (p < 0.005) (Fig. 2C).
Correlations between adiponectin concentration 
and age, results of anthropometric measurements, 
and biochemical parameters
Analysis of correlation showed that the adiponectin 
concentration obtained at the acute phase of IgAV 
had an association with nephritis, which presented as 
a negative correlation with serum creatinine concentra-
tion (r = –0.437, p = 0.02). 
Discussion
Our study is the first to estimate the expression of 
adiponectin in children with IgAV. Adiponectin as 
a vascular-protective and anti-inflammatory hormone is 
the focus of many researchers currently. Initially it was 
thought to be synthesised exclusively by adipocytes; 
however, recent studies have shown that it is also ex-
pressed by other cell types including kidney mesangial 
cells [3]. As an anti-inflammatory protein it enhances 
the production of nitric oxide, reduces formation of 
reactive oxygen species in human neutrophils, inhibits 
monocyte adhesion, and stimulates anti-inflammatory 
interleukin 10 (IL-10) production by macrophages [7, 
8]. Increased serum levels of adiponectin were found 
in single studies conducted on patients with several 
inflammatory diseases such as rheumatoid arthritis [9], 
cystic fibrosis (CF) [10], inflammatory bowel diseases 
(IBD) [11], and lupus nephritis [12]. However, the exact 
reason for the high observed adiponectin concentration 
in these diseases is not evident. Moreover, the results of 
other studies carried out in patients with CF and IBD 
did not confirm the above observations [13–14].
We showed that patients with IgAV had signifi-
cantly higher concentrations of adiponectin in serum 
in comparison with the control group. Therefore, the 
main reason of IgAV is small vessel inflammation we 
propose that this observation may result from the role of 
adiponectin in modulating the inflammatory response. 
In several previously published studies the authors 
reported that the endothelial function was closely re-
lated to plasma adiponectin level and was impaired in 
hypoadiponectinaemia [15, 16]. 
Additionally, we revealed markedly higher levels 
of adiponectin in children without renal involvement 
compared to those with nephritis. In an analysis of the 
correlation we found a negative relationship between 
adiponectin level and serum creatinine concentra-
tion. Further investigation demonstrated that a low 
adiponectin level increased the risk of nephritis in the 
course of IgAV. We hypothesise that this finding may 
be connected with the protective role of this hormone 
on the kidneys. As was revealed by other researchers, 
adiponectin not only modulates the process of inflam-
mation and oxidative stress in kidneys but also alters 
podocyte function [17–20]. 
Our assumptions are confirmed by studies con-
ducted on patients with IgA nephropathy (IgAN), 
which documented that lower adiponectin concentra-
tion promotes inflammation and sclerosis in this disease 
[3–5]. Previously, Uchida et al. evaluated the effect of 
glucocorticoid pulse therapy on adiponectin concentra-
tion in adult patients with IgAN and revealed that after 
this therapy the plasma adiponectin levels increased [4]. 
Subsequently, Iwasa et al. proved that serum adiponec-
tin level was an independent determinant of arterio-
sclerosis in IgAN adult patients and suggested that this 
hormone may prevent renal arteriosclerosis [5]. Finally, 
Inoue et al. revealed that secretion of adiponectin in 
human mesangial cells was suppressed after stimula-
tion by aberrantly glycosylated IgA1. What is more, 
the authors observed a downregulation of adiponectin 
expression in the glomeruli in kidney biopsy specimens 
from patients with IgAN [3]. Because the pathogenic 
mechanisms of renal involvement in IgAV and IgAN are 
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supposed to be identical, the data presented above seem 
to be the best for comparison with our observations.
We also documented a significant male predomi-
nance in the group with nephritis, which was reported 
previously and is considered as a risk factor for renal 
involvement in the course of IgAV [21]. In connection 
with the fact that the serum adiponectin level is even 
two-fold higher in females than in males [22], we 
compared its concentration between genders in study 
and control groups and revealed significant differences 
only in the IgAV group. This observation suggests that 
in healthy children adiponectin levels are comparable 
between genders and only during disease do their lower 
concentrations in boys become significant. However, 
whether the male gender is a risk factor for nephritis 
due to the lower potential for adiponectin increase 
during IgAV requires further investigation.
After the follow-up period we demonstrated signifi-
cantly lower adiponectin levels in all patients from the 
study group in comparison with the value obtained at 
inclusion. However, only in children with renal com-
plications were the adiponectin levels not markedly 
decreased. This observation might be connected with 
the fact that most of them still presented nephrological 
complications.   
A limitation of our study was the relatively small 
sample size and also the mild character of kidney 
involvement. However, in a single-centre research it 
is difficult to collect a more numerous study group of 
children because the course of IgAV is mostly benign 
and serious kidney complications are very rare. Another 
limitation is the gender distribution with male predomi-
nance in the study group, but, as was previously noted, 
this is related to the characteristics of the disease.
Conclusions
Our study revealed that serum adiponectin levels 
increased significantly in patients with IgAV. What is 
more important, we documented that higher risk of 
nephritis in the course of the disease was associated 
with lower concentration of this hormone. Due to 
anti-inflammatory and kidney protective functions of 
adiponectin, our observations suggest its potential role 
in the prevention of renal injury in the course of IgAV. 
However, because the above observations are herein 
first described in the literature, there is a need to con-
duct further large scale multi-centre clinical studies to 
confirm these results.
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